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Identifying the genes underlying susceptibility to human
disease represents a major objective of current biomedical
research. Increasingly, the focus of such gene-discovery
efforts has shifted from rare, monogenic conditions towards
the common conditions (such as diabetes, asthma, neuro-
psychiatric disorders and cancers) that account for the major-
ity of human illness and mortality. These common conditions
are termed ‘multifactorial’ because, in each case, susceptibil-
ity is attributed to the effects of genetic variation at a number
of different genes and their interaction with relevant environ-
mental exposures. The expectation is that identification and
characterization of the genes that provide the inherited com-
ponent of susceptibility will lead to substantial advances in
our understanding of disease and, in turn, to improvements
in diagnostic accuracy, prognostic precision, and the range
and targeting of available therapeutic options. 
The ‘traditional’ route to gene discovery - for the rarer, mono-
genic, Mendelian diseases at least - has been positional
cloning. Typically, the gene responsible for a trait is first
localized by linkage analysis to a small interval (ideally less
than 1 centiMorgan, cM) by successive rounds of linkage
mapping within families. Next, each of the handful of genes
mapping to the interval so defined is assessed for their poten-
tial functional relevance to the disease and screened for etio-
logical mutations. Well over 1,000 Mendelian diseases have
been mapped using modifications of this procedure [1]. 
To date, the application of similar strategies to the identification
of susceptibility genes underlying common, complex multi-
factorial traits has brought only limited success. The explana-
tion for this pedestrian progress stems from the weak
relationship between genotype - at any given locus - and phe-
notype that characterizes multifactorial traits. Not only does
this mean that the correlation signals that we seek to detect
by linkage analysis or population-based association studies
are that much weaker in the first place, it also limits the
capacity of these tools to provide precise estimates of disease-
gene localization. The regions of interest defined through
complex-trait linkage studies - even when analysis has
involved thousands of families segregating the trait of interest
- regularly exceed 30 cM in size, and contain many hundreds
of genes. Large genomic intervals of interest can also be
defined through the analysis of major chromosomal
rearrangements, duplications and deletions, implicated in the
development of cancers and certain multisystem syndromes. 
Difficulties with the positional cloning approach have led
many investigators to favor a strategy based primarily on
identifying susceptibility variants through direct examina-
tion of biological candidates (‘the candidate gene approach’).
This strategy, too, has proven something of a disappoint-
ment [2], precisely because ignorance about the biology of
complex diseases has typically frustrated efforts to define
biological candidacy with any confidence. 
Abstract
Improved techniques for defining disease-gene location and evaluating the biological candidacy of
regional transcripts will hasten disease-gene discovery. The key to accelerating the discovery of susceptibility genes for
multifactorial conditions clearly lies in developing improved
strategies for refining both disease-gene location and assess-
ments of biological candidacy (see Figure 1). This article
describes some recent developments, with an emphasis on
their impact on susceptibility-gene identification in man. 
New methods for defining susceptibility-gene
location 
Linkage analysis seeks to provide disease-gene localization
through the direct observation of recombination events
within families. Whilst it has proven an extremely effective
tool for detecting and localizing the rare, penetrant variants
that underlie most monogenic conditions (see above), it is all
too often underpowered when it comes to the search for the
common variants of modest penetrance that are generally
held to influence susceptibility to common traits [3]. 
Association (or more strictly, linkage disequilibrium)
mapping, in contrast, seeks to localize susceptibility variants
through the analysis of allele distributions in populations,
relying on the observed consequences of unobserved recom-
bination events during population history. Provided the sus-
ceptibility variant itself (or a variant highly correlated with it)
is amongst the markers typed, association mapping is, gener-
ally, more powerful than linkage analysis [4]. Furthermore,
because the extent of linkage disequilibrium (LD) within pop-
ulations (typically tens of kilobases) is much less than that of
linkage within families (typically tens of megabases), much
tighter disease gene localization is possible. 
One promising positional-cloning strategy for complex
traits, therefore, starts with a preliminary linkage analysis to
identify regions of interest. Following replication in other
datasets, the strongest regions are then selected for LD
mapping to refine susceptibility-gene location. Unless there
is extensive allelic and locus heterogeneity, the association
signal within such linked regions should be appreciable and,
in principle, readily detected provided that a sufficiently
dense set of markers is typed [5]. The markers that are used
are increasingly likely to be single-nucleotide polymor-
phisms (SNPs). Although there have been several notable
successes from this approach [6-8], widespread implemen-
tation has been stifled by the daunting scale associated with
any exhaustive LD screen across a large genomic interval.
Several ongoing developments can be expected to facilitate
such large-scale ‘brute force’ LD mapping efforts in the
years to come. First, an increasingly comprehensive catalog
of common variants [9] is providing the reagents for future
LD studies. Second, a growing appreciation of the high-res-
olution structure of LD in human populations [10] indicates
that most common variation within a region can be ‘cap-
tured’ by typing only a subset of the available variants (so-
called ‘haplotype-tagging’ or htSNPs) [11]. The HapMap
project is currently characterizing the haplotype structure
of the genome in major ethnic groups, thereby defining
htSNPs for use in future positional cloning endeavors.
Third, improved genotyping platforms and strategies, using
extensive multiplexing [12] and/or pooled DNA samples
[13], promise to provide significant improvements in
throughput combined with necessary reductions in cost and
DNA consumption. 
Significant issues remain unresolved, however. The density
of SNPs required to provide a comprehensive survey of
common disease variation remains unclear. On current evi-
dence - except in population isolates, in which LD may be
more extensive - a mean density exceeding one (haplotype-
tagging) variant every five kilobases looks to be necessary,
and considerably more in regions of high haplotypic diver-
sity [14]. The relative importance of common versus rare
variants in complex-trait susceptibility remains a con-
tentious issue with enormous practical implications: a strat-
egy based on common htSNPs will be poor at detecting rare
penetrant mutations, and substantial allelic heterogeneity
may seriously compromise the power of LD-mapping
approaches [15]. The pros and cons of focusing the survey of
a region on gene-related sequence [16] as opposed to an
indiscriminate ‘gene-blind’ set of markers remain to be
established. Finally, there remain significant analytical
issues as to how best to analyze the large amounts of data
that will arise. High-density LD surveys of several large
genomic regions are now underway for a range of diseases.
Whether successful or not in terms of disease-gene discov-
ery, these ‘pilot’ studies, each generating several million
genotypes, will help to address various unresolved issues,
and inform future efforts. 
Several groups have elected to bypass the linkage step and
proceed directly to genome-wide LD analyses. Many of
these efforts have been rather optimistic in terms of the
density of markers typed, although interesting data have
emerged from studies of population isolates [17]. In such
populations - such as French Canadians and Finns - which
have often grown from a limited number of recent founder
individuals, LD may extend much further than in non-
isolate populations, reducing the number of markers that
need to be typed to obtain genome-wide coverage. Recently,
a study of over 90,000 gene-based variants provided a valu-
able proof-of-principle by detecting a strong association
between a variant in the LTA gene and myocardial infarc-
tion in Japanese [16]. 
These early studies indicate that it will be increasingly possi-
ble to translate the success of positional cloning (in the strict
sense of the term, using positional mapping alone without
reference to function) from rare, monogenic syndromes to
common multifactorial traits. At the moment, the main
obstacle remains the prodigious costs of implementing these
strategies on the scale that is necessary. 
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biological candidacy
The candidate-gene approach relies on matching known or
presumed gene functions to the known or presumed biology
of the disease or phenotype under investigation. The aim is
to identify genes with a strong prior claim to involvement in
disease susceptibility and to prioritize these for analyses
seeking evidence of disease-associated variation. Sadly,
however, the history of candidate-gene studies, particularly
for complex traits, has been characterized by a swathe of
unsubstantiated, unreplicated claims and relatively few
proven associations [1,2]. Amongst the many methodological
and cultural reasons for this failure [18], two concern us
here. First, because in general we know so little about the
mechanisms responsible for complex diseases, any test of
biological candidacy is necessarily speculative. Second, it is
worth remembering that significant susceptibility effects are
only likely to be found in a small minority of the set of genes
whose products are directly involved in disease pathogenesis
[19]. As a result, for most complex traits there are - even for
genes with apparently robust biological credentials - rela-
tively low prior odds (that is, odds estimated prior to the
start of any genotyping) that variants within that gene play a
major role in disease susceptibility. These low prior odds
need to be borne in mind when interpreting the results of
association studies [18]. 
The expectation is that application of the growing range of
massively parallel genome-wide ‘-omics’ technologies - from
transcriptional profiling to metabonomics and beyond - will
provide a basis for refining assessments of biological candi-
dacy and identifying candidates with better prior odds. A
growing number of examples attest to the potential of these
strategies. Most to date have featured the use of expression
data, with lists of promising candidates generated on the
basis of both expression state (tissue expression profiles)
and studies of differential expression. For some tissues,
restricted or preferential tissue expression patterns have
provided valuable clues to biological candidacy: for example,
almost half of the 51 genes underlying monogenic retinal
phenotypes are specifically or preferentially expressed in the
retina [20]. For many complex traits, however, multisystem
involvement and uncertainties over the most appropriate
choice of tissues for study have limited the value of this
approach. Even when the choice of target tissue is clear,
sparse expression-state data in public repositories (for
example, for the adipocyte) and/or inaccessibility of the
tissues of interest (such as the pancreatic  cell) have often
compromised progress. 
Genome-wide studies of differential expression - whether
undertaken by differential display, representational differ-
ence analysis or microarrays - have obvious potential to
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Figure 1
Candidate-gene identification past and present. In the past, the emphasis was on using linkage analysis to direct positional-cloning efforts, and on the
application of our limited understanding of disease pathogenesis to select biologically relevant candidate genes. Now, additional techniques are providing
new routes to the identification of disease-susceptibility genes. See text for further details. 
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candidacyprovide valuable clues to disease-associated pathways,
thereby identifying candidates for genetic studies. Work on
rodent models has predominated in this area; limitations on
tissue accessibility, uncertainties over tissue selection, and
concerns about the ‘noise’ arising from studies of ‘free-range’
subjects, have impeded equivalent studies in humans. But
recent studies demonstrating that insulin resistance and
type 2 diabetes are consistently and reproducibly associated
with downregulation, in human skeletal muscle, of a coregu-
lated set of oxidative phosphorylation genes [21,22] are reas-
suring and confirm the capacity to highlight candidates with
key regulatory roles, in this case, PGC1-/PPARGC1. Associ-
ation studies of this gene have already generated positive,
though as yet inconsistent, findings [23].
As with any transcript-profiling study, design is all-impor-
tant. Comparisons between ‘diseased’ and ‘control’ tissue
will favor direct detection of variants involved in gene regu-
lation or mRNA stability, but not those that modify protein
sequence (with some notable exceptions [24]). Where possi-
ble, there is considerable merit in complementing such
‘disease versus control’ candidate-mining efforts with addi-
tional transcriptional comparisons designed to detect genes
regulated by environmental or pharmacological interven-
tions pertinent to the disease phenotype. For example, in a
study of the levels of high-density lipoprotein (HDL) choles-
terol in baboons, transcript levels were studied in relation to
both HDL levels and response to high-fat diet [25]. It is
important to remember that candidacy mining using expres-
sion-profiling methods will perform poorly where trait sus-
ceptibility is governed by variation within genes with
low-level and/or restricted expression (for example, limited
to tight temporal and/or developmental windows).
Other genome-wide (-omics) technologies should, in time,
provide equivalent power for defining novel etiological path-
ways and putative candidates. Studies aiming to define the
protein markers of disease have often been limited by the
scalability of conventional proteomic technologies [26], but
recent advances (for example, the identification of putative
plasma protein biomarkers for ovarian cancer [27]) should,
as the relevant biomarkers are characterized, provide valu-
able biological insights and new candidates. The same is true
of metabonomics-based analyses [28]. 
Whilst considerable advances will arise from each platform in
isolation, the key to a robust and comprehensive understand-
ing of etiological pathways, and to a full description of disease
pathogenesis that will maximally inform candidate selection,
will be data integration. By synthesizing and modeling the
changes that occur at the level of the genome, message,
protein, post-translational modification, metabonome and
physiome, such integration should lead to construction of a
‘biological atlas’ of each disease or phenotype of interest
[29]. Within such a framework, data from ‘distal’ modalities,
such as metabonomics and intermediate physiology, which
more closely reflect the visible phenotype of interest, can
inform the interpretation of ‘proximal’ modalities, such as
expression data. This should help to distinguish, for
example, those transcriptional changes that are directly
related to disease etiology from those that are secondary or
epiphenomenal. As an example, two large consortia - the
UK-based Biological Atlas of Insulin Resistance (BAIR) [30]
and the US-based Diabetes Genome Anatomy Project - have
established complementary programs to reconstruct the
development of type 2 diabetes and obesity, through coordi-
nated transcriptional, proteomic, metabonomic, biochemical
and physiological analyses in multiple tissue samples taken
from rodent models at various stages of trait progression.
One outcome of these studies will be an improved frame-
work for the selection of functional candidates for genetic
studies in man. 
Integrating location and function
Despite the undoubted power of the approaches described
above, we believe that the strongest routes to robust candi-
date identification will come from integrating the positional
and functional routes to candidacy. Broadly speaking, there
are two main ways by which this integration is being
achieved. The first involves the use of functional genomic
readouts - expression levels, protein levels, metabolite
spectra, and so on - as ‘endophenotypes’ to be subjected to
the same genome-wide quantitative trait linkage (and LD)
strategies as have been traditionally performed on disease
phenotypes. In the most comprehensive study published to
date [31], genome-wide expression profiling on liver tissue
from 111 F2 mice segregating obesity-related traits identified
the only two transcripts that jointly met the following three
criteria: first, physical location within a region on murine
chromosome 2 harboring a locus for fat-pad mass, one of the
obesity phenotypes of interest; second, linkage mapping of
the variation in their expression levels to the same genomic
location (indicating cis-acting expression effects); and third,
transcriptional differences related to fat-pad mass trait
values. Preliminary studies in human pedigrees have con-
firmed that familial aggregation of expression phenotypes
remains detectable even under the less controlled circum-
stances inevitable in human studies [31,32], setting the stage
for future linkage studies to map the loci that influence these
expression levels, be they acting in cis (promoter variation
within the genes themselves, for example) or in trans (via
transcription factors).
The second way that integration is being achieved represents
an updating of the ‘positional candidate’ strategy [33] to take
account of contemporary informatics and functional
genomics, and represents the intersection of positional
cloning and functional candidate-selection approaches. As
described above, the region of interest defined by a genome-
wide linkage scan is generally around 30-40 megabases
(about 1% of the genome) and contains several hundred
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hensive LD-based survey of such large regions, there is
obvious interest in the use of biological candidacy as a
means for evaluating and prioritizing regional transcripts for
detailed mutation detection and association analysis.
Looked at from another angle, one can view the genomic
localization afforded by linkage studies (or physical mapping
efforts) as providing a powerful basis for filtering the output
of what tend to be relatively non-specific functional assess-
ments of candidacy (such as descriptions of expression state
and analyses of genome-wide differential expression).
It is of course, nowadays, an entirely straightforward matter
to download the identities of all known genes mapping to a
region of interest, and to skim through the list looking for
obvious biological candidates. On occasion, this has proven
extremely successful: inspection of the list highlights a single
strong candidate, subsequently confirmed as the etiological
locus [7]. In such circumstances, defining the overlap of func-
tion and location is a trivial matter. In general, however, a
respectable prima facie case for disease involvement can be
made for a substantial proportion of the genes mapping to
the interval, making further prioritization essential if the list
of genes to be studied is to be brought to manageable levels. 
The challenge then lies in bringing together as many lines of
evidence as possible about the biology of the genes mapping to
the interval, and to relate these data to the biology of the
disease or phenotype of interest. This is most definitely a non-
trivial exercise, not least because it implies the need for an
intimate dialogue between bioinformaticians on the one hand
- as the people best placed to assemble information on gene
biology - and biologists and clinicians on the other - as the
people with expertise in the biology of the disease. The
number of parameters that could potentially inform posi-
tional-candidate prioritization is substantial (see Table 1). For
many of these, however, the datasets currently available are
too sparse to offer much in the way of discriminant power, and
expression data has been most widely used to date. 
Expression state has proven particularly useful in defining
positional candidates for retinal [20,34,35] and cochlear
[36] diseases; and de novo serial analysis of gene expression
(SAGE) of the substantia nigra transcriptome was used as a
tool for prioritizing positional candidates for Parkinson’s
disease [37]. Clearly, these types of data will be most valu-
able in circumstances where, as with Parkinson’s, there are
strong grounds for implicating specific tissues in disease
pathogenesis. 
Application of expression-state data is not limited to selec-
tion on the basis of predicted tissue distribution, but can be
extended to incorporate knowledge regarding subcellular
localization [38]. Prior linkage analysis in families with the
French-Canadian subtype of Leigh syndrome had mapped
the gene responsible to chromosome 2p, and the biology of
the disease strongly implicated genes involved in mitochon-
drial function. Publicly available mRNA expression data
were used to identify which of the regional transcripts had
mRNA expression patterns resembling those of known mito-
chondrial genes. This analysis, together with data emerging
from a proteomic survey of isolated mitochondria, pin-
pointed a single transcript, LRPPRC, which was confirmed
as the disease gene by mutation screening in pedigrees seg-
regating the disorder [38]. 
The most productive strategy to date, in animal models at
least, has been the integration of information from posi-
tional localization with that from differential expression
analysis. To identify genes underlying lipid phenotypes in
baboons, a chromosomal-region-specific expression array -
covering a region of interest defined by prior linkage - was
used to detect regional transcripts with expression levels
correlated with HDL-cholesterol levels and with the
response to a high-fat diet [25]. In the NOD mouse model of
autoimmune diabetes, Eaves and colleagues [39] used
genome-wide transcriptional comparisons between NOD,
NOD-derived congenic, and control strains to relate differ-
ential expression patterns to the locations of known suscep-
tibility loci, and thereby to prioritize candidates. A similar
congenic-based approach has been used successfully in rat
models of hypertension [24,40]. The human homologs of
these regional transcripts represent strong disease-suscepti-
bility candidates. Issues of tissue availability will mean that,
for many diseases, rodent models are likely to provide a
more reliable source of such candidates than equivalent
studies on human tissues. 
For most of the studies described above, the expression data
used were generated de novo, in part because of the patchy
and disorganized nature of publicly available expression
data. Certainly, expression-state data for many critical
human tissues remain limited, and there is a clear need for a
concerted effort to generate comprehensive transcript lists
for a broad range of human tissues and cell types [41]. Such
information, coupled with recent developments in setting
standards for expression data [42,43] and the predicted
expansion in usable, publicly available expression-profiling
data [44], will hopefully reduce the need for costly de novo
work and make expression-related data increasingly relevant
to the evaluation of disease-gene candidacy. 
As the breadth and depth of data available concerning each
gene grows, two major challenges will need to be met, if these
data are to be used optimally for assessments of disease-gene
candidacy. The first challenge lies in displaying all these dis-
parate data types - and related text-based information from
the literature - to the user in such a way as to inform and
assist decisions about positional-candidate prioritization.
Through the EnsMart [45] component of the Ensembl data-
base, it is already possible to combine information on
genomic location, expression state (defined by a controlled
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attributes encoded by Gene Ontology terms [46,47]. The
GeneSeeker program allows users to query on the basis of
position, expression state and some phenotypic attributes
[48]. Key to continued progress in this area is the construc-
tion of suitable controlled vocabularies or ontologies that
permit uniform comparison of data from differing platforms,
databases and species. These will allow additional attributes
(see Table 1) to become increasingly accessible to the candi-
date-prioritization process. 
The second challenge will be the development of, and valida-
tion of, heuristics for candidate-gene prioritization that take
account of the range of data available and the domain exper-
tise of the biologist as regards the disease or phenotype of
interest. One interesting approach will be to consider the
topography of expression, regulatory and protein-protein
interaction networks; proteins that are known to be hubs of
such networks show higher degrees of conservation [49] and
may therefore be more likely disease candidates. Other
current efforts have used Gene Ontology terms to group genes
with similar properties, identifying potential candidates on the
basis of potential functional overlap with known disease genes
previously implicated in related diseases [50,51]. 
In conclusion, we have outlined some of the approaches
currently being developed and applied to aid the identification
of the genes that influence susceptibility to the major dis-
eases that afflict mankind. These approaches are increas-
ingly contingent on the integration of information from
diverse data sources, and success will be dependent on over-
coming the significant cultural and technical challenges that
this imposes. 
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